Regeneron Pharmaceuticals, Inc.

  • This Pharma Stock Is Ready to Reach New Heights

    By Kanak Kanti - August 12, 2013 | Tickers: BAYRY.PK, REGN, SNY

    Earlier this year, in May, Regeneron Pharmaceuticals (NASDAQ: REGN) was soaring on news of FDA approval of the Eylea injection. The market valued the company at almost $27 billion at that time. It has come down quite a bit now to nearly $25 billion. Things are now happening again at this counter, with the company preparing to submit an application for approval of Eylea for a new indication, and an more »

  • Have These 3 Biotechs Reached A Peak?

    By Brian Nichols - August 9, 2013 | Tickers: JAZZ, REGN, SNTS

    On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection. Therefore, can these stocks go any higher? Or, have these stocks reached their peak?

    New Product Launch Suggests More Upside

    For the third consecutive quarter, Santarus (NASDAQ: SNTS) raised its 2013 top line guidance, and significantly beat revenue and earnings expectations for the quarter. The stock is up more »

  • Is This Biotech Slowing?

    By Brandy Betz - August 9, 2013 | Tickers: REGN, RHHBY, SNY

    Regeneron Pharmaceuticals (NASDAQ: REGN) closed Tuesday down over 6% following a second quarter report that missed estimates. A particular cause for concern was the slowed sales growth for macular degeneration drug Eylea. Were investors right to run away?

    If you Google Regeneron’s second quarter right now, you’ll see an odd mix of headlines touting either Eylea’s slowdown or its sales jump. So which is it? It’s more »

  • Should You Keep an Eye on These Eye Treatment Biotechs?

    By Leo Sun - August 8, 2013 | Tickers: AMPE, NVS, REGN, RHHBY

    Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector. Two eye diseases -- wet AMD (age-related macular degeneration) and DME (diabetic macular edema) -- are at the center of a big battle that includes Roche (NASDAQOTH: RHHBY), Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Ampio Pharmaceuticals (NYSEMKT: AMPE).

    Wet (neovascular) AMD causes abnormal blood vessels to more »

  • Is There Pipeline Potential in These 3 Biotech Stocks?

    By Sherrie Stone - August 7, 2013 | Tickers: PCYC, REGN, SRPT

    It is not uncommon for a biotechnology company to be valued solely on the potential of one drug. For many small and midcap biotechs, the potential of lead drugs has already led to large stock gains. Therefore, let’s look further down the pipeline at the market’s most exciting biotechs, and determine whether future upside exists.

    Treating The Disease, Not The Symptoms

    Regeneron Pharmaceuticals (NASDAQ: REGN) has rallied 700 more »

  • Is This Biopharmaceutical Company Ahead Of Its Time?

    By Sherrie Stone - July 18, 2013 | Tickers: ALXN, RPTP, REGN

    In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company in particular, Regeneron Pharmaceuticals (NASDAQ: REGN), is crossing the line as a dual-threat developer of both kinds of drugs. Here's why that might make it worthy of your investment.

    The Difference In Therapeutic Approach

    Drugs that earn orphan designations treat rare diseases. Orphan drugs are more more »

  • 4 Noteworthy Upgrades That You Should Question

    By Brian Nichols - July 13, 2013 | Tickers: MCP, REGN, WDAY, XLNX

    On Friday we saw several stock-moving upgrades in preparation of a long week of earnings; here are four that really caught my eye. These are upgrades that I would definitely ignore.

    The best of the worst

    After a 64% one-year loss, Molycorp (NYSE: MCP) has gained 22% over the last month, and much of those gains have been caused by analyst upgrades. Byron Capital likes Molycorp; his “Strong Buy” rating more »

  • How Should You Diversify a $10,000 Portfolio?

    By Brian Nichols - July 8, 2013 | Tickers: AAPL, BBY, REGN

    New age diversification is investing in the 21st century, and understanding that very few have the patience or the discipline to buy, hold, and forget for decades at a time.

    In today’s information age, people like to be active, and follow their investments closely. Thus, new age diversification allows each investment to serve a purpose in your portfolio.

    In previous Motley Fool articles, I touched on this topic with more »

  • 3 Monday Morning Upgrades I’m Buying Now

    By Brian Nichols - July 2, 2013 | Tickers: AAPL, BBY, REGN

    There were countless market-moving upgrades on Monday morning -- but here are three in particular that I believe are most attractive and that I personally am buying.

    A Bullish Day for Biotech

    The entire biotech space is moving higher in response to the bid for Onyx Pharmaceuticals, especially those with Orphan blockbusters. Regeneron Pharmaceuticals (NASDAQ: REGN) is one of those stocks, but also got an upgrade to produce an extra boost more »

  • An Insider and His Wife Are Buying This Pharma Stock

    By Meena Krishnamsetty - June 28, 2013 | Tickers: MRK, NVS, REGN, TEVA, VRX

    According to a filing with the SEC, between June 11 and June 12, Valeant Pharmaceuticals (NYSE: VRX) Board member Lloyd Segal directly purchased 2,800 shares of the stock at an average price of $83.85 per share. This gave him a total of slightly more than 21,000 shares of the stock, and came at the same time as his wife purchased close to 400 shares of Valeant.

    We more »

  • 3 Companies With High EPS Growth Forecasts

    By Shweta Dubey - June 26, 2013 | Tickers: ASML, ET, REGN, CRM

    Earnings per share, or EPS, shows the rate at which a company has grown its profitability. EPS growth is a good fundamental indicator of the future prospects of a company. Increased revenue and high profit margin drive the EPS growth of a company, and investors generally look for companies with higher EPS growth. Let’s delve into the strategies of three companies that are estimated to have more than 25 more »

  • Is This Stock A Value Trap?

    By Sherrie Stone - June 24, 2013 | Tickers: REGN, SPPI

    Spectrum Pharmaceuticals (NASDAQ: SPPI) got crushed with a downgrade from Credit Suisse that led to a 6.3% loss on Monday. The stock is now trading at $7.50, 33% lower than it began the year (at $12). But what many don’t realize is that Spectrum at $7.50 is actually more expensive than it was at $12.00

    This Is Not A Cheap Stock

    Back in March, Spectrum more »

  • Is This Eye Drug Worth The Hype?

    By Sherrie Stone - June 21, 2013 | Tickers: AMPE, REGN, RHHBY

    Editor’s Note: The original article incorrectly references Lucentis’ and Eylea’s dosage instructions and Roche's vaccine market share. This has been corrected and Motley Fool sincerely apologizes for the error.

    Regeneron Pharmaceuticals (NASDAQ: REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea.

    Regeneron Pharmaceuticals is a $25 more »

  • Valeant Biting More Than it Can Chew

    By Kanak Kanti - June 13, 2013 | Tickers: NVS, REGN, VRX

    While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry continues to be marked by M&A. Valeant Pharmaceuticals (NYSE: VRX) is one such company that is known to swear by the philosophy of aggressive growth-by-acquisition. Last month, the company announced a mega-deal, the biggest acquisition yet by the company at $8.7 billion, to more »

  • The First Real Cure in the $25 billion Asthma Market?

    By Kanak Kanti - June 12, 2013 | Tickers: AZN, GSK, REGN

    Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic. It is painful experience watching kids wheezing and groaning under an attack on the playground, looking for their inhalers. A number of therapies, including tablets and inhalers, are available to treat asthma; however, asthma has no real cure to date. Current products are only meant to control asthma attacks. Therefore, patients are more »

  • A $90 Price Target for This Biotech! How’s It Figured?

    By Brian Nichols - May 31, 2013 | Tickers: AEGR, ALXN, REGN, SRPT

    Aegerion Pharmaceuticals (NASDAQ: AEGR) is currently trading higher by 13% after having its price target raised to $90 by Canaccord – which is now the highest target on the stock. The stock is trading at $68.50 after a one-year 380% gain due to the recent FDA approval of its drug Juxtapid. However, I believe the stock has gotten ahead of itself, and that there is no basis for a $90 more »

  • 3 Significant Insider Sells in Healthcare Worth Noting

    By Brian Nichols - May 31, 2013 | Tickers: BMRN, REGN, VRTX

    It’s no secret that the insiders of a company know what’s happening before us. They know trends, demand, supply, and to most of us, it makes no sense for an executive to sell shares prior to a large takeover or raised earnings guidance. Thus, when an insider sells shares we automatically assume the worst – and in some cases – we are correct!

    Two Examples of Insider Selling

    While investors more »

  • Is College Debt a Drag on These Promising Healthcare Stocks

    By Harriet Tramer - May 29, 2013 | Tickers: AMGN, GILD, IBB, REGN

    Some stocks seem to have all the luck, offering the best of both worlds. They are cutting edge or at least a bit adventuresome as their products travel into uncharted territory. Innovations that they have in their pipelines are promising to push the margins even a bit further outward some time soon. Yet, despite the fact they are moving ahead at a blazing speed, they are still managing to lay more »

  • Is This Momentum Stock’s Rally Over?

    By Brian Nichols - May 22, 2013 | Tickers: ALXN, REGN

    Regeneron Pharmaceuticals (NASDAQ: REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260. The drugmaker has been one of the best-performing stocks of the last few years, trading higher regardless of market trend. After many years of gains, some are wondering whether now's the time to take profits. Here's why I think it's not.

    A more »

  • Why This Stock's Crash is a Buying Opportunity

    By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

    It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

    Allergan’s Outlook

    It was almost a tale more »

  • Page 1 of 3